Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cost Effectiveness and Resource Allocation
Published in: Cost Effectiveness and Resource Allocation 1/2017

Open Access 01-12-2017 | Research

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Authors: Phil McEwan, Samantha Webster, Thomas Ward, Michael Brenner, Anupama Kalsekar, Yong Yuan

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2017

Login to get access

Abstract

Background

As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with faster disease progression and has fewer treatment options, historically, than other HCV genotypes. This analysis aims to estimate the comparative cost-effectiveness of two recently licenced interferon-free regimens for the treatment of HCV genotype 3.

Methods

Utilising a published Markov model and results of a matching-adjusted indirect comparison of recently published clinical trial data (ALLY-3 and VALENCE, respectively), 12 weeks of treatment with daclatasvir + sofosbuvir (DCV + SOF) was compared to 24 weeks of treatment with sofosbuvir + ribavirin (SOF + RBV). UK-specific model inputs were used to inform a cost-utility analysis of these regimens.

Results

In the base case analysis, DCV + SOF was found to be dominant over SOF + RBV in treatment-naïve patients, patients that had previously been treated, and patients that are intolerant to, or ineligible for, interferon-containing regimens. Given the low rates of treatment currently observed in the UK, DCV + SOF was also compared to no treatment in the interferon-ineligible/intolerant patients, and may be considered cost-effective with an incremental cost-effectiveness ratio of £8817.

Conclusions

When compared to 24 weeks of SOF + RBV, 12 weeks of treatment with DCV + SOF results in improved quality of life and reduced total costs, and therefore is likely to represent significant clinical and economic value as a treatment option for genotype 3 HCV infection.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and Cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2010;140(4):1182–8.CrossRefPubMedPubMedCentral
5.
de Oliveria Andrade LJ, D’Oliveira A, Melo RC, De Souza EC, Costa Silva CA, Paraná R. Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis. 2009;1(1):33–7.CrossRefPubMedPubMedCentral
6.
Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Mullhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009;51(4):655–66.CrossRefPubMed
7.
Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression—a systematic review and meta-analysis. J Viral Hepat. 2011;18(11):745–59.CrossRefPubMed
8.
McMahon BJ, Bruden D, Bruce MG, Livingston S, Christensen C, Homan C, et al. Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastroenterology. 2010;138(3):922–31.CrossRefPubMed
9.
Larsen C, Bousquet V, Delarocque-Astagneau E, Pioche C, Roudot-Thoraval F, Desenclos JC. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France. J Med Virol. 2010;82(10):1647–54.CrossRefPubMed
10.
van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.CrossRefPubMed
11.
Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat. 2011;18(10):e516–22.CrossRefPubMed
12.
Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of US Veterans with HCV. Hepatology. 2014;60(1):98–105.CrossRefPubMedPubMedCentral
13.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199.CrossRef
14.
McEwan P, Kim R, Yuan Y. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl Health Econ Health Policy. 2013;11(1):53–63.CrossRefPubMed
15.
McEwan P, Ward T, Yuan Y, Kim R, L’Italien G. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology (Baltimore, Md). 2013;58(1):54–64.CrossRef
16.
McEwan P, Ward T, Chen C-J, Lee M-H, Yang H-I, Kim R, et al. Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection. Value Health Reg Issues. 2014;3:5–11.CrossRef
17.
Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418–31.CrossRefPubMed
18.
19.
20.
Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess (Winchester, England). 2007;11(11):1–205.
21.
Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55(1):49–57.CrossRefPubMed
22.
Townsend R, McEwan P, Kim R, Yuan Y. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health. 2011;14(8):1068–77.CrossRefPubMed
23.
Janssen Ltd. Telaprevir for the treatment of genotype 1 chronic hepatitis C. High Wycombe: Janssen Ltd; 2011.
24.
Personal Social Services Research Unit. Unit costs of health and social care 2013. Section 16.2: The hospital & community health services (HCHS) index; 2013.
25.
26.
27.
28.
Nottingham University Hospitals NHS Trust, Medical Research Foundation. Host and viral factors associated with outcomes of infection with hepatitis C virus (HCV Research UK). Nottingham: Nottingham University Hospitals NHS Trust; 2014.
29.
Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology. 2015;61:1127–35.CrossRefPubMedPubMedCentral
30.
Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993–2001.CrossRefPubMed
31.
Swallow E. Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis C genotype 3: a matching-adjusted indirect comparison. Vienna: The International Liver Congress; 2015.
32.
33.
Restelli U, Alberti A, Lazzarin A, Bonfanti M, Nappi C, Croce D. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy. Eur J Health Econ. 2016. pp. 1–8. doi:10.​1007/​s10198-016-0865-3.
34.
Crespo J, Cabezas J, Sacristán B, Olcoz JL, Pérez R, De la Vega J, et al. Barriers to HCV treatment in the era of triple therapy: a prospective multi-centred study in clinical practice. Liver Int. 2015;35(2):401–8.CrossRefPubMed
35.
Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol. 2011;56(2):320–5.CrossRefPubMed
36.
Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antivir Res. 2014;107:23–30.CrossRefPubMed
37.
Poynard T, Moussalli J, Munteanu M, Thabut D, Lebray P, Rudler M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013;59(4):675–83.CrossRefPubMed
38.
Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58(5):1598–609.CrossRefPubMedPubMedCentral
39.
Metadata
Title
Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
Authors
Phil McEwan
Samantha Webster
Thomas Ward
Michael Brenner
Anupama Kalsekar
Yong Yuan
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cost Effectiveness and Resource Allocation / Issue 1/2017
Electronic ISSN: 1478-7547
DOI
https://doi.org/10.1186/s12962-017-0077-4

Other articles of this Issue 1/2017

Cost Effectiveness and Resource Allocation 1/2017 Go to the issue

Research

Cost effectiveness of pre-referral antimalarial treatment in severe malaria among children in sub-Saharan Africa

Research

Costs and savings associated with a pharmacists prescribing for minor ailments program in Saskatchewan

Research

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece

Review

Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review

Methodology

Defining a staged-based process for economic and financial evaluations of mHealth programs

Research

Modeling the potential impact of emerging innovations on achievement of Sustainable Development Goals related to maternal, newborn, and child health